Erratum to: Rheumatol Ther (2016) 3:5–29 DOI 10.1007/s40744-016-0031-5
In the original version, the second paragraph (last sentence) of the section “Efficacy of Secukinumab in Patient Subgroups” under heading FUTURE 1 AND FUTURE 2, a value is incorrect. The correct sentence should read as:
The Week 52 observed data were 62.1% for secukinumab 300 mg, 48.3% for secukinumab 150 mg, and 63.2% for secukinumab 75 mg (Fig. 12b).
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Footnotes
The online version of the original article can be found under doi:10.1007/s40744-016-0031-5.